科研动态期刊摘要

中国近期研究者发起的基因编辑疗法试验的经验教训

Nature Medicine · 2026-11-11

摘要

《自然·医学》,在线发表:2026年11月11日;doi:10.1038/s41591-026-04768-x 中国实验性细胞和基因疗法试验期间发生的数起死亡事件似乎揭示了治理与监管方面的漏洞。高风险疗法的临床监管需要新增一层独立的外部审查。

English
Lessons from recent investigator-initiated trials of gene-editing therapies in China

Nature Medicine, Published online: 11 November 2026; doi:10.1038/s41591-026-04768-x Several deaths during trials of experimental cell and gene therapies in China appear to reveal gaps in governance and oversight. A new layer of independent external review is needed for clinical supervision of high-risk therapies.

内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界